Skip to main content

Advertisement

SpringerLink
Log in

The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis

  • Original Article
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

The aim of this study was to assess the efficacy and safety of a once-yearly zoledronic acid treatment for Chinese women with postmenopausal osteoporosis in Taiwan and Hong Kong. This post hoc subpopulation analysis, from the Health Outcome and Reduced Incidence with Zoledronic Acid One Yearly Pivotal Fracture Trial, enrolled 323 Chinese women with osteoporosis who were randomly given either annual infusions of zoledronic acid or placebo for 3 consecutive years. The incidence of fractures and changes in bone mineral density (BMD) were measured; adverse events (AEs) and tolerability were recorded and assessed. The results of this study at 36 months demonstrate that there was a significantly reduced risk of morphometric vertebral fracture and clinical vertebral fracture in subjects treated with zoledronic acid (P < 0.05). In addition, there were significant increases of BMD by 4.9%, 4.3%, and 7.0% in the total hip, femoral neck, and trochanter, respectively, in the zoledronic acid group compared with the placebo group (P < 0.001 for all comparisons). The incidences of AEs were comparable between the two groups. Thus, once-yearly zoledronic acid treatment showed bone protection effects by reducing the risk of vertebral fracture and increasing BMD in Chinese women with postmenopausal osteoporosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Melton LJ III (1995) How many women have osteoporosis now? J Bone Miner Res 10:175–177

    Article  PubMed  Google Scholar 

  2. Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761–1767

    Article  PubMed  Google Scholar 

  3. Lynn HS, Lau EM, Au B, Leung PC (2005) Bone mineral density reference norms for Hong Kong Chinese. Osteoporos Int 16:1663–1668

    Article  PubMed  CAS  Google Scholar 

  4. Tsai KS, Tai TY (1997) Epidemiology of osteoporosis in Taiwan. Osteoporos Int 7(suppl 3):S96–S98

    Article  Google Scholar 

  5. Cooper C (1997) The crippling consequences of fractures and their impact on quality of life. Am J Med 103:12S–17S (discussion 17S–19S)

    Article  PubMed  CAS  Google Scholar 

  6. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353:878–882

    Article  PubMed  CAS  Google Scholar 

  7. MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, Mojica W, Timmer M, Alexander A, McNamara M, Desai SB, Zhou A, Chen S, Carter J, Tringale C, Valentine D, Johnsen B, Grossman J (2008) Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 148:197–213

    PubMed  Google Scholar 

  8. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C, Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group (2002) Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23:570–578

    Article  PubMed  CAS  Google Scholar 

  9. Hwang JS, Tu ST, Yang TS, Chen JF, Wang CJ, Tsai KS (2006) Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis. Osteoporos Int 17:373–378

    Article  PubMed  CAS  Google Scholar 

  10. Yen ML, Yen BL, Jang MH, Hsu SH, Cheng WC, Tsai KS (2000) Effects of alendronate on osteopenic postmenopausal Chinese women. Bone (NY) 27:681–685

    CAS  Google Scholar 

  11. Hwang JS, Chen JF, Yang TS, Wu DJ, Tsai KS, Ho C, Wu CH, Su SL, Wang CJ, Tu ST (2008) The effects of strontium ranelate in Asian women with postmenopausal osteoporosis. Calcif Tissue Int 83:308–315

    Article  PubMed  CAS  Google Scholar 

  12. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541

    Article  PubMed  CAS  Google Scholar 

  13. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY, Hip Intervention Program Study Group (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333–340

    Article  PubMed  CAS  Google Scholar 

  14. Cramer JA, Amonkar MM, Hebborn A, Altman R (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21:1453–1460

    Article  PubMed  CAS  Google Scholar 

  15. Penning-van Beest FJ, Erkens JA, Olson M, Herings RM (2008) Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 19:511–517

    Article  PubMed  CAS  Google Scholar 

  16. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P et al (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653–661

    Article  PubMed  CAS  Google Scholar 

  17. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, HORIZON Pivotal FT (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis (see comment). N Engl J Med 356:1809–1822

    Article  PubMed  CAS  Google Scholar 

  18. Eastell R, Black DM, Boonen S, Adami S, Felsenberg D, Lippuner K, Cummings SR, Delmas PD, Palermo L, Mesenbrink P, Cauley JA, HORIZON Pivotal FT (2009) Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. J Clin Endocrinol Metab 94:3215–3225

    Article  PubMed  CAS  Google Scholar 

  19. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809

    Article  PubMed  CAS  Google Scholar 

  20. Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, Christiansen C, Civitelli R, Drezner MK, Recker RR, Bolognese M, Hughes C, Masanauskaite D, Ward P, Sambrook P, Reid DM (2006) Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 54:1838–1846

    Article  PubMed  CAS  Google Scholar 

  21. Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, Christiansen C, Rowell L, Mairon N, Bonvoisin B, Drezner MK, Emkey R, Felsenberg D, Cooper C, Delmas PD, Miller PD (2006) Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 65:654–661

    Article  PubMed  CAS  Google Scholar 

  22. Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK (2005) The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 139:101–111

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This project was funded by Novartis Co. Inc., as a phase IIIB clinical trial in Taiwan and Hong Kong. We wish to thank the clinical staff at all study sites for their important contributions to the study.

Author information

Authors and Affiliations

  1. Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Linkou, Kaohsiung, Taiwan, ROC

    Jawl-Shan Hwang & Jung-Fu Chen

  2. Department of Orthopedic Surgery, Chi-Mei Medical Center, Tainan, Taiwan, ROC

    Lin-Show Chin

  3. Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, School of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC

    Tzay-Shing Yang

  4. Department of Orthopedic Surgery, Min-Sheng General Hospital, Taoyuan, Taiwan, ROC

    Po-Quang Chen

  5. National Taiwan University Hospital, Taipei, Taiwan, ROC

    Po-Quang Chen

  6. Department of Internal Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan, ROC

    Keh-Sung Tsai

  7. 3/F, School of Public Health, Prince of Wales Hospital, Jockey Club Centre for Osteoporosis Care and Control, The Chinese University of Hong Kong, Shatin, Hong Kong

    Ping Chung Leung

Authors
  1. Jawl-Shan Hwang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lin-Show Chin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jung-Fu Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tzay-Shing Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Po-Quang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Keh-Sung Tsai
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ping Chung Leung
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ping Chung Leung.

About this article

Cite this article

Hwang, JS., Chin, LS., Chen, JF. et al. The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis. J Bone Miner Metab 29, 328–333 (2011). https://doi.org/10.1007/s00774-010-0223-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-010-0223-y

Keywords

Search

Navigation